Public trial registry of the CCC-Munich

Trial A61811112

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
A61811112
World
Full title
:

A phase IIIB, randomized, active controlledopen-labeled study of Sunitinib 37,5 mg daily vs. Imatinib 800 mg daily in the treatment of patients with GIST who havehad PD while on 400 mg daily of Imatinib

World
EudraCT number
:
World
Responsible organization
:
KUM - Med3 - Medizinische Klinik und Poliklinik III Lmu
Indications
Classification Code Description
- C15-C19 GIST
Trial design
World
Phase
:
IIIB
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / 2013-07-02
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.